[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IS2494B - Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni - Google Patents

Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni

Info

Publication number
IS2494B
IS2494B IS5568A IS5568A IS2494B IS 2494 B IS2494 B IS 2494B IS 5568 A IS5568 A IS 5568A IS 5568 A IS5568 A IS 5568A IS 2494 B IS2494 B IS 2494B
Authority
IS
Iceland
Prior art keywords
morpholinol
treatment
sexual dysfunction
sexual
dysfunction
Prior art date
Application number
IS5568A
Other languages
English (en)
Other versions
IS5568A (is
Inventor
Frederick Morgan Phillip
Lee Musso David
Joseph Partridge John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS5568A publication Critical patent/IS5568A/is
Publication of IS2494B publication Critical patent/IS2494B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5568A 1998-01-21 2000-07-20 Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni IS2494B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (2)

Publication Number Publication Date
IS5568A IS5568A (is) 2000-07-20
IS2494B true IS2494B (is) 2009-02-15

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5568A IS2494B (is) 1998-01-21 2000-07-20 Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni

Country Status (30)

Country Link
US (2) US6274579B1 (is)
EP (2) EP1829544A1 (is)
JP (1) JP2002501025A (is)
KR (1) KR100568063B1 (is)
CN (2) CN1255389C (is)
AP (1) AP1229A (is)
AT (1) ATE365042T1 (is)
AU (1) AU755536B2 (is)
BR (1) BR9907203A (is)
CA (1) CA2318268A1 (is)
CY (1) CY1106828T1 (is)
DE (1) DE69936335T2 (is)
DK (1) DK1047428T3 (is)
EA (1) EA002410B1 (is)
EE (1) EE04452B1 (is)
ES (1) ES2288012T3 (is)
HR (2) HRP20000494B1 (is)
HU (1) HUP0100900A3 (is)
ID (1) ID26334A (is)
IL (2) IL161942A0 (is)
IS (1) IS2494B (is)
NO (2) NO326878B1 (is)
NZ (3) NZ505809A (is)
PL (1) PL193622B1 (is)
PT (1) PT1047428E (is)
SG (1) SG115489A1 (is)
SK (1) SK10912000A3 (is)
TR (1) TR200002126T2 (is)
WO (1) WO1999037305A1 (is)
YU (1) YU67102A (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
EP1051164A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP2003511410A (ja) * 1999-10-13 2003-03-25 グラクソ グループ リミテッド 肥満症の治療のためのモルホリノール誘導体
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
MXPA04011203A (es) * 2002-05-17 2005-07-14 Univ Duke Metodo para tratar la obesidad.
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7384941B2 (en) * 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US7375111B2 (en) 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
WO2005042503A1 (en) * 2003-10-27 2005-05-12 Smithkline Beecham Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
JP2007517901A (ja) * 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005110405A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007079470A2 (en) 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AR063958A1 (es) 2006-11-09 2009-03-04 Orexigen Therapeutics Inc Metodos para administrar medicaciones para la perdida de peso
KR101479324B1 (ko) 2006-11-09 2015-01-05 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010121022A1 (en) 2009-04-15 2010-10-21 Research Triangle Institute Monoamine reuptake inhibitors
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
ES2687095T3 (es) 2010-05-21 2018-10-23 Research Triangle Institute Fenilimorfolinas y análogos de las mismas
AU2011255456B2 (en) 2010-05-21 2017-01-19 Dignity Health Doing Business As St. Joseph's Hospital And Medical Center And Barrow Neurological Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
US6391875B2 (en) 2002-05-21
NO326878B1 (no) 2009-03-09
NO20003721D0 (no) 2000-07-20
DK1047428T3 (da) 2007-10-08
AP2000001869A0 (en) 2000-09-30
CN1255389C (zh) 2006-05-10
AU755536B2 (en) 2002-12-12
BR9907203A (pt) 2000-10-17
AU2328099A (en) 1999-08-09
PT1047428E (pt) 2007-09-07
HUP0100900A2 (hu) 2002-05-29
CA2318268A1 (en) 1999-07-29
HRP20000494B1 (en) 2009-02-28
PL342012A1 (en) 2001-05-07
JP2002501025A (ja) 2002-01-15
EP1047428A1 (en) 2000-11-02
NZ520349A (en) 2004-02-27
ES2288012T3 (es) 2007-12-16
EP1829544A1 (en) 2007-09-05
HRP20000494A2 (en) 2000-12-31
IL161942A0 (en) 2005-11-20
HRP20051024A2 (hr) 2006-04-30
DE69936335D1 (de) 2007-08-02
US20020019396A1 (en) 2002-02-14
KR100568063B1 (ko) 2006-04-07
SK10912000A3 (sk) 2001-04-09
EP1047428B1 (en) 2007-06-20
KR20010034285A (ko) 2001-04-25
US6274579B1 (en) 2001-08-14
WO1999037305A1 (en) 1999-07-29
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
IS5568A (is) 2000-07-20
YU67102A (sh) 2004-12-31
NO20003721L (no) 2000-09-19
HUP0100900A3 (en) 2002-08-28
NO20083529L (no) 2000-09-19
ID26334A (id) 2000-12-14
EE200000438A (et) 2001-12-17
NZ505809A (en) 2002-09-27
TR200002126T2 (tr) 2000-12-21
EP1047428A4 (en) 2001-12-19
EA200000691A1 (ru) 2001-04-23
CN1294513A (zh) 2001-05-09
NZ529316A (en) 2004-05-28
CY1106828T1 (el) 2012-05-23
EE04452B1 (et) 2005-04-15
CN1203858C (zh) 2005-06-01
EA002410B1 (ru) 2002-04-25
PL193622B1 (pl) 2007-02-28
ATE365042T1 (de) 2007-07-15
SG115489A1 (en) 2005-10-28
AP1229A (en) 2003-12-04
DE69936335T2 (de) 2008-02-28

Similar Documents

Publication Publication Date Title
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
IS6303A (is) Notkun retígabíns til meðhöndlunar á taugasjúkdómatengdum sársauka
GT199900013A (es) Tratamiento de la disfuncion sexual femenina.
IS6785A (is) EP4 viðtakahindrar til meðhöndlunar á liðagigt
NO20005255D0 (no) Pyrazolpyrimidin-CGMPPDE5-inhibitorer for behandling av seksuell dysfunksjon
IS5085A (is) Nefholssamsetningar til meðhöndlunar á kynferðistruflunum
DE60020327D1 (de) Wasserbehandlungsvorrichtung
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
IS6195A (is) Notkun á mótefnum gegn CD20 til meðhöndlunar á þegahöfnunarveiki
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
NO995823D0 (no) Terapeutisk middel for ereksjonsdysfunksjon
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
DK1008558T3 (da) Fremgangsmåde til behandling af organisk spildevand
IS7136A (is) Aðferð til meðhöndlunar á svefnleysi á frumstigi
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
NO20013596D0 (no) Slambehandling
DE50009813D1 (de) Kombinationpräparat zur behandlung von sexueller dysfunktion
NO20013146D0 (no) Middel for behandling av synscellefunksjonsforstyrrelser
DE60022086D1 (de) Wasserbehandlung
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi